SEC Filing Summary: Tharimmune, Inc. (THAR)
Business Context and Reporting Period
This Form 8-K was filed by Tharimmune, Inc. (formerly Hillstream BioPharma, Inc.) on September 21, 2023. The registrant is a Delaware corporation with its principal executive offices in Bridgewater, New Jersey. The company is listed on The Nasdaq Capital Market and is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
- Corporate Name Change: The company changed its name from Hillstream BioPharma, Inc. to Tharimmune, Inc.
- Effective Date: The name change became effective on September 25, 2023.
- Trading Symbol: The common stock now trades under the new ticker symbol "THAR" on The Nasdaq Capital Market.
- Legal Filing: A Certificate of Amendment to the Certificate of Incorporation was filed with the Delaware Secretary of State on September 21, 2023.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The document focuses solely on the procedural execution of the name change and the associated press release issued on September 22, 2023.
Investor Verification Checklist
- Verify the new ticker symbol "THAR" on The Nasdaq Capital Market.
- Confirm the effective date of the name change (September 25, 2023) for trading and record-keeping purposes.
- Review the attached Certificate of Amendment (Exhibit 3.1) for details on the amended Certificate of Incorporation.
- Check the press release (Exhibit 99.1) for any additional strategic context regarding the rebranding.